R&D Pipeline

Our Pipeline and Its Potential

Beyond Air Pipeline & Market Size

Product Indication Development
Status
Key Dates(1) US Sales
Potential(2)
Worldwide Sales
Potential(2)
LungFitPH
Ventilator compatible
In-Hospital use for PPHN and cardiac surgery Final preparations for PMA PMA filing 2H 2020

US Launch 1H 2021
>$300m >$600m
LungFit COVID-19 Pilot studies in progress Pilot study data 2H 2020 N/A N/A
LungFit Bronchiolitis 3 Pilot studies complete

Pivotal-ready
Pivotal Starts 4Q21

US Launch 2023
>$500m

Beyond Air to commercialize
>$1.2b
LungFit Home Nontuberculous mycobacteria (NTM) lung infection Pilot phase 4Q20 start for pilot

Study with self-administration
>$1b >$2.5b
LungFit Home Severe exacerbations due to lung infections in COPD patients Pre-clinical Pilot study start 2H21 >$2.5b >$6b
Solid Tumors Multiple solid tumors Pre-clinical

Initial data presented

AACR June 2020

TBD TBD

†Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.

(1) All dates are based on projections and appropriate financing, anticipated first launch on a global basis pending appropriate regulatory approvals

(2) All figures are Company estimates for peak year sales: Global sales potential includes US sales potential

Important Safety Information

Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.